Bextra, Vioxx Require Stronger Warnings, Additional Study, Cmte. Finds
Executive Summary
Pfizer's Bextra requires additional clinical trials to clarify an observed cardiovascular signal, a joint FDA advisory committee on COX-2 inhibitor safety said